2022
SURG-23. EFFICACY OF LASER INTERSTITIAL THERMAL THERAPY (LITT) FOR NEWLY DIAGNOSED AND RECURRENT IDH WILD-TYPE GLIOBLASTOMA
de Groot J, Kim A, Prabhu S, Rao G, Laxton A, Fecci P, O'Brien B, Sloan A, Chiang V, Tatter S, Mohammadi A, Placantonakis D, Strowd R, Chen C, Hadjipanayis C, Khasraw M, Sun D, Piccioni D, Sinicrope K, Campian J, Kurz S, Williams B, Smith K, Tovar-Spinoza Z, Leuthardt E. SURG-23. EFFICACY OF LASER INTERSTITIAL THERMAL THERAPY (LITT) FOR NEWLY DIAGNOSED AND RECURRENT IDH WILD-TYPE GLIOBLASTOMA. Neuro-Oncology 2022, 24: vii256-vii257. PMCID: PMC9660753, DOI: 10.1093/neuonc/noac209.989.Peer-Reviewed Original ResearchLaser interstitial thermal therapyIDH wild-type glioblastomaConventional surgical resectionWild-type glioblastomaInterstitial thermal therapySurgical resectionProspective multicenter registryMaximal safe resectionTime of diagnosisGross total resectionPrimary brain tumorsCytoreductive approachMedian OSAdjuvant temozolomideHospital stayMulticenter registryAdverse eventsOverall survivalRecurrent patientsClinical outcomesRecurrent GBMTraditional resectionMedian lengthSurgical approachTreatment optionsEfficacy of laser interstitial thermal therapy (LITT) for newly diagnosed and recurrent IDH wild-type glioblastoma
de Groot JF, Kim AH, Prabhu S, Rao G, Laxton AW, Fecci PE, O’Brien B, Sloan A, Chiang V, Tatter SB, Mohammadi AM, Placantonakis DG, Strowd RE, Chen C, Hadjipanayis C, Khasraw M, Sun D, Piccioni D, Sinicrope KD, Campian JL, Kurz SC, Williams B, Smith K, Tovar-Spinoza Z, Leuthardt EC. Efficacy of laser interstitial thermal therapy (LITT) for newly diagnosed and recurrent IDH wild-type glioblastoma. Neuro-Oncology Advances 2022, 4: vdac040. PMID: 35611270, PMCID: PMC9122789, DOI: 10.1093/noajnl/vdac040.Peer-Reviewed Original ResearchMedian overall survivalLaser interstitial thermal therapyOverall survivalRecurrent patientsWild-type glioblastomaRecurrent glioblastomaGlioblastoma patientsProspective multicenter registry dataMulticenter registry dataRecurrent glioblastoma patientsChemo/radiationPrimary brain tumorsInterstitial thermal therapyIDH wild-type glioblastomaAdjuvant chemotherapyAdverse eventsImproved survivalClinical outcomesPromoter methylation statusMultivariable differenceSurgical approachTreatment optionsRegistry dataUS CentersTumor volume
2021
SURG-02. Stereotactic Laser Ablation (SLA) followed by consolidation stereotactic radiosurgery (SRS) as a treatment strategy for brain metastasis that recurred locally after initial radiosurgery (BMRS): a collaborative institutional experience
Pena-Pino I, Ma J, Hori Y, Fomchenko E, Dusenbery K, Reynolds M, Wilke C, Yuan J, Barnett G, Chiang V, Mohammadi A, Chen C. SURG-02. Stereotactic Laser Ablation (SLA) followed by consolidation stereotactic radiosurgery (SRS) as a treatment strategy for brain metastasis that recurred locally after initial radiosurgery (BMRS): a collaborative institutional experience. Neuro-Oncology Advances 2021, 3: iii23-iii23. PMCID: PMC8351296, DOI: 10.1093/noajnl/vdab071.095.Peer-Reviewed Original ResearchStereotactic laser ablationStereotactic radiosurgeryOverall survivalTreatment strategiesLocal controlDays of SRSSymptomatic radiation necrosisMedian overall survivalSystemic disease progressionRepeat stereotactic radiosurgeryIndependent clinical trialsInitial radiosurgerySteroid therapyBrain metastasesClinical outcomesRadiation necrosisFavorable outcomeClinical trialsDisease progressionFLAIR volumeInstitutional experiencePatientsCE volumeRadiosurgeryLocal failureClinical Significance of PDCD4 in Melanoma by Subcellular Expression and in Tumor-Associated Immune Cells
Tran TT, Rane CK, Zito CR, Weiss SA, Jessel S, Lucca L, Lu BY, Oria VO, Adeniran A, Chiang VL, Omay SB, Hafler DA, Kluger HM, Jilaveanu LB. Clinical Significance of PDCD4 in Melanoma by Subcellular Expression and in Tumor-Associated Immune Cells. Cancers 2021, 13: 1049. PMID: 33801444, PMCID: PMC7958624, DOI: 10.3390/cancers13051049.Peer-Reviewed Original ResearchPDCD4 expressionImproved survivalTumor-Associated Immune CellsTumor microenvironmentNeoplastic progressionBrain metastasis outcomesExtracranial metastatic diseaseMelanoma brain metastasesNatural killer cellsBrain metastasis samplesImmune cell infiltrationImmune cell subsetsMultiple tissue microarraysExpression of PDCD4Brain metastasesMetastatic diseaseClinical outcomesKiller cellsClinicopathological variablesIntracranial metastasesCell subsetsCell infiltrationCell death 4Immune cellsPrimary melanoma
2020
LITT for Metastatic In-Field Recurrence
Sujijantarat N, Danish S, Chiang V. LITT for Metastatic In-Field Recurrence. 2020, 51-64. DOI: 10.1007/978-3-030-48047-9_5.Peer-Reviewed Original ResearchLaser interstitial thermal therapyNeurological outcomeRadiation necrosisProgression-free survival ratesInitiation of steroidsMulticenter prospective seriesSystemic therapy optionsAdverse neurological outcomesLarge prospective studiesSuitable surgical candidatesBlood-brain barrierInterstitial thermal therapyContrast-enhancing volumeBrain metastasesSurgical candidatesProspective seriesClinical outcomesImaging changesSymptom managementCancer survivorsProspective studyTherapeutic managementTherapy optionsFLAIR volumeInvasive approach
2018
Stereotactic Radiosurgery for Trigeminal Neuralgia in Patients With Multiple Sclerosis: A Multicenter Study.
Xu Z, Mathieu D, Heroux F, Abbassy M, Barnett G, Mohammadi AM, Kano H, Caruso J, Shih HH, Grills IS, Lee K, Krishnan S, Kaufmann AM, Lee JYK, Alonso-Basanta M, Kerr M, Pierce J, Kondziolka D, Hess JA, Gerrard J, Chiang V, Lunsford LD, Sheehan JP. Stereotactic Radiosurgery for Trigeminal Neuralgia in Patients With Multiple Sclerosis: A Multicenter Study. Neurosurgery 2018, 84: 499-505. PMID: 29688562, DOI: 10.1093/neuros/nyy142.Peer-Reviewed Original ResearchConceptsRecurrence-free rateTrigeminal neuralgiaStereotactic radiosurgeryPain responsePain controlMultiple sclerosisMS-related trigeminal neuralgiaFavorable initial responseReasonable pain controlRetrospective cohort studyMedian latency periodLarge patient seriesGamma Knife CenterFacial pain responsesFacial numbnessCohort studyClinical outcomesMedical managementPatient seriesMulticenter studySurgical interventionPatientsLatency periodRisk profileInitial response
2016
Spine Stereotactic Body Radiotherapy Outcomes in Patients with Concurrent Brain Metastases
Colaco RJ, Park HS, Laurans MS, Chiang VS, Yu JB, Husain ZA. Spine Stereotactic Body Radiotherapy Outcomes in Patients with Concurrent Brain Metastases. Cureus 2016, 8: e679. PMID: 27563505, PMCID: PMC4985044, DOI: 10.7759/cureus.679.Peer-Reviewed Original ResearchSpine stereotactic body radiotherapyConcurrent brain metastasisStereotactic body radiotherapyOverall survivalSpine metastasesLocal controlBrain metastasesMultivariable analysisOne-year local controlOne-year overall survivalCox proportional hazards regressionMedian patient ageProportional hazards regressionLog-rank testMann-Whitney testCBM patientsSurvival prognosticatorPain controlComplete stagingPatient ageSpinal metastasesClinical outcomesHazards regressionRadioresistant histologiesBody radiotherapy
2014
Significance of histology in determining management of lesions regrowing after radiosurgery
Nath SK, Sheridan AD, Rauch PJ, Yu JB, Minja FJ, Vortmeyer AO, Chiang VL. Significance of histology in determining management of lesions regrowing after radiosurgery. Journal Of Neuro-Oncology 2014, 117: 303-310. PMID: 24504499, DOI: 10.1007/s11060-014-1389-2.Peer-Reviewed Original ResearchConceptsBrain metastasesTumor cellsLocal controlSignificance of histologyWorse local controlResidual tumor cellsPost-treatment imagingManagement of lesionsOngoing patient managementInflammatory changesClinical outcomesResidual tumorSymptomatic enlargementAmbiguous etiologyHistologic findingsPatient outcomesPatient managementBrain specimensStereotactic radiosurgeryHistopathologic interpretationLesionsTissue specimensResectionPatientsMetastasis
2013
A Clinical Model for Identifying Radiosensitive Tumor Genotypes in Non–Small Cell Lung Cancer
Johung KL, Yao X, Li F, Yu JB, Gettinger SN, Goldberg S, Decker RH, Hess JA, Chiang VL, Contessa JN. A Clinical Model for Identifying Radiosensitive Tumor Genotypes in Non–Small Cell Lung Cancer. Clinical Cancer Research 2013, 19: 5523-5532. PMID: 23897899, DOI: 10.1158/1078-0432.ccr-13-0836.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAnaplastic Lymphoma KinaseAntineoplastic AgentsBrain NeoplasmsCarcinoma, Non-Small-Cell LungErbB ReceptorsFemaleGenotypeHumansLung NeoplasmsMaleMiddle AgedMutationProtein Kinase InhibitorsRadiation ToleranceReceptor Protein-Tyrosine KinasesRecurrenceTranslocation, GeneticTumor BurdenConceptsNon-small cell lung cancerCell lung cancerEML4-ALK translocationGamma knife treatmentLocal controlTumor genotypeLung cancerEGFR mutationsCox proportional hazards modelDistant brain controlDistant brain recurrenceGamma knife radiotherapyEGFR kinase domain mutationsSuperior local controlField local controlKRAS mutation statusProportional hazards modelKinase domain mutationsEGF receptorMetastasis sizeBrain recurrenceBrain metastasesField recurrenceClinical outcomesIndependent predictorsStereotactic body radiotherapy: a new paradigm in the management of spinal metastases
Husain ZA, Thibault I, Letourneau D, Ma L, Keller H, Suh J, Chiang V, Chang EL, Rampersaud RK, Perry J, Larson DA, Sahgal A. Stereotactic body radiotherapy: a new paradigm in the management of spinal metastases. CNS Oncology 2013, 2: 259-270. PMID: 25054466, PMCID: PMC6166530, DOI: 10.2217/cns.13.11.Peer-Reviewed Original ResearchConceptsSpine stereotactic body radiotherapyStereotactic body radiotherapyBody radiotherapySpinal metastasesMajor serious adverse eventsRole of surgerySerious adverse eventsConventional palliative radiotherapyPain controlPalliative radiotherapyAdverse eventsClinical outcomesConventional radiotherapyRadiotherapyEffective dosesMetastasisPatientsSurgeryTumorsDoses